NR4A2 and Parkinson disease: BRF110 is a synthetic small molecule designed to specifically activate the NURR1-RXR heterodimer, whose oral treatment has shown to protect dopaminergic neurons from α-syn and to restore dopamine synthesis in preclinical models of PD (Spathis et al., 2017).